Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Summary

Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia

Eligibility

Inclusion Criteria:

* Women aged 18 to 75 years old as of the date of study registration.
* Patients with histologically confirmed invasive adenocarcinoma.
* Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status.
* Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
* Patients with a left ventricular ejection fraction (LVEF) ≥55%.
* Patients who have agreed to participate in this trial and have provided written consent.

Exclusion Criteria:

* Patients with a history of breast cancer treatment
* Patients with a history of chemotherapy, radiation therapy, immunotherapy, or biotherapy for malignancies other than breast cancer
* Patients with infectious diseases
* Patients with serious illnesses that may affect this clinical trial: cardiovascular disease, kidney disease, liver disease, endocrine disease, tumors, or diabetes
* Other individuals deemed by the clinical trial investigators to be unable to participate in the trial.

Conditions3

Browse More Trials